Meet the Inaugural Gene Therapy Candidates
The two gene therapy clinical trials for Wilson disease (WD) launched by Ultragenyx and Vivet Therapeutics are underway! Here, we introduce the WD community to two people who are trailblazers in these studies that will show us if gene therapy works as a treatment for the rare genetic liver disease. Emily signed up for the Ultragenyx trial, and Warren volunteered for the Vivet trial.

They are both in their 40’s. Both are married with a young child, and they both live east of the Mississippi and north of the Mason-Dixon Line. They’re both Caucasian, brunette and wear glasses. They’re the only ones in their respective families with WD. And both were diagnosed from the copper deposits found in their corneas, called Kayser-Fleischer rings.
Read More

Why They Said ‘Yes’ to Gene Therapy
We continue the story of two trailblazers who are among the first Wilson disease (WD) patients to volunteer for one of the two gene therapy clinical trials now underway for our rare genetic liver disorder. Emily signed up for the Ultragenyx trial and Warren volunteered for the Vivet trial. In our Winter 2023 newsletter we introduced them to the WD community. Emily received her diagnosis five years before on her 35th birthday, while Warren was diagnosed in 1980 at age seven. Emily is a wife and mom to a four-year-old son and works as a school secretary. Warren is a husband and dad to an 11-year-old daughter and had to give up his job as a preacher due to WD complications.

The story of their patient experience left off with Emily and Warren facing the decision of whether or not to participate in a trial designed to determine if gene therapy in WD patients is safe, and works.
Read More

Important Update on UX701 Gene Therapy:

On November 3, 2026, Ultragenyx announced that it is discontinuing development of UX701, an investigational gene therapy for Wilson disease, after clinical trial results did not demonstrate sufficient effectiveness to advance to Phase 3.

We recognize that this news is disappointing for the Wilson disease community. Below is a letter from the Ultragenyx team explaining the decision, what it means for clinical trial participants, and the next steps.

November 3, 2026

Dear Wilson Disease Community,

The Ultragenyx team is reaching out with an important update to meet your request for ongoing updates about UX701, our investigational gene therapy for the potential treatment of Wilson disease. Ultragenyx has made the difficult decision to discontinue development of UX701 based on preliminary efficacy data from Phase 1/2 that have not demonstrated sufficient efficacy to move the program into Phase 3. Patients who received UX701 as part of the Cyprus2+ clinical study will continue to receive long-term safety monitoring. No new patients will receive UX701. We recognize this news is disappointing for the Wilson disease community. We are extremely grateful to the patients and families who participated in the Phase 1/2 study and the investigators who care for them. Additional information, including what happens next, are below.

Preliminary Phase 1/2 results and rationale for discontinuing development of UX701 program:

• The Phase 1/2 study enrolled 20 patients into four sequential dosing cohorts with the goal of identifying a dose with an appropriate safety and efficacy profile for further investigation in a pivotal phase 3 study. All patients in the Phase 1/2 study have now been followed for at least 52 weeks.

• The decision was made to discontinue development of UX701 due to lack of efficacy. While some patients in several dose groups showed improvements in copper-based biomarkers, and several of them were able to discontinue standard of care medications and maintain acceptable copper levels for several years, these effects were inconsistent across dose cohorts. The highest dose group did not show a substantial improvement in biomarkers or efficacy compared to prior cohorts.

• The decision to discontinue development was not made for safety reasons. Up until now, UX701 was well tolerated and has had an acceptable safety profile to date, including in the highest dose group and in participants who received the revised immunomodulation regimen.

What happens next:

• Patients who have received UX701 will continue to be monitored for long-term safety. Individual participants and their families will be contacted directly by their PI about specific next steps.

• We are committed to sharing the full study results to help inform future learnings for the field. We plan to publish a manuscript and present the results at a scientific congress in 2027.

We express our deep appreciation to the patients, families, investigators, study site staff, CRO partners, and the Wilson disease patient community for their support and contributions to this program.

Individuals participating in the Cyprus2+ study should direct questions to their study site. Community members can direct questions to patientinquiry@ultragenyx.com.

Sincerely,

Andrew Grimm on behalf of the UX701 Team

Gene Therapy

Gene therapy is a technique designed to treat or prevent disease. When a gene mutation causes a protein to be missing or faulty, gene therapy may be able to restore the normal function of that protein. In the case of Wilson disease, patients have a faulty copy of the ATP7B gene, which is responsible for transporting excess copper out of the liver.

To learn more about how gene therapy might help people with Wilson disease, view this video produced by The American Society of Gene & Cell Therapy (ASGCT):

One gene therapy study is underway for patients with Wilson disease. The study, being conducted by Ultragenyx, is designed to deliver a one-time infusion of a normal, working copy of the ATP7B gene into the liver called UX701. Study locations, enrollment criteria and study design continue to evolve. For the most up-to-date information about the UX701 gene therapy study being conducted by Ultragenyx visit https://clinicaltrials.gov/ and enter “NCT04884815” in the search bar.

You can find additional information about the Ultragenyx trial here:

The chief medical officer of Ultragenyx provided this presentation at the WDA’s 2023 Virtual Conference:

Prime Medicine is studying gene editing as a possible treatment for Wilson disease and presented potentially promising data on its preclinical gene editing studies at scientific meetings in late 2024 and 2025. In the laboratory, or preclinically, scientists were able to correct the faulty ATP7B gene that causes WD with its gene editing technology.

To learn how prime editing works you can watch a video here.

Prime Medicine is conducting a research study called Prime-0211 for adults living with Wilson disease (WD). This is a pre-screening study, which means no treatment is being given and no investigational therapy is being tested. The purpose of this study is to collect information that may help guide future research in Wilson disease, including possible studies of gene-editing approaches. Details on how to participate can be found here and for the most up-to-date information visit https://clinicaltrials.gov/ under NCT07226622.

Vivet Therapeutics made the difficult decision in October 2024 to terminate its VTX-801 gene therapy trial after infusing four patients at two different dosing levels. Data gathered at that time from the two doses that were tested showed that while the gene therapy was safe, it did not show a significant enough effect. Bumping up to the next dosing level would require additional funding.

Donations

Why Your Donation Matters

Your donation to the Wilson Disease Association does more than keep the lights on—it powers education, awareness and action. With your support, we’re able to maintain vital resources like this website, produce trusted educational materials, fund critical research and host events that bring together patients, caregivers and medical professionals. Most importantly, your generosity helps raise awareness so more people are diagnosed earlier and treated effectively—giving them the best chance at a full, healthy life.

When you give, you’re not just supporting an organization—you’re joining a powerful movement to change the future of Wilson disease. You’ll stay informed about the latest in research and treatment, gain access to exclusive webinars and educational resources, and remain connected to a global community that understands. For more than 40 years, our shared commitment has fueled advances in care, deepened understanding, and amplified the voices of those affected by Wilson disease. Together, we’re building a stronger, more informed future.

WILSON DISEASE ASSOCIATION

Contact Us